Results 111 to 120 of about 20,527 (318)

Dupilumab for nasal polyposis [PDF]

The Lancet, 2020
Lipworth, Brian, Chan, Rory, Kuo, Chris RuiWen   +2 more
openaire   +4 more sources

Transcriptomic Analysis of Allergic Patch Test Reactions in Non‐Atopic Patients: A Comparative Study Across Multiple Allergens

Allergy, EarlyView.
This study investigated the immune mechanisms underlying allergic contact dermatitis (ACD) in response to four distinct allergens by using RNA sequencing in a cohort of 40 non‐atopic patients and 19 controls. A shared ACD imprinting across allergens showed strong innate and adaptive responses, dominated by type 1 immunity but with mixed immune ...
David Pesqué, Evelyn Andrades, Pau Berenguer‐Molins, Júlia Perera‐Bel, Miquel Clarós, Marta Bódalo‐Torruella, Mònica González‐Farré, Fernando Gallardo, Ramon M. Pujol, Ana M. Giménez‐Arnau   +9 more
wiley   +1 more source

Dupilumab improves eosinophilic otitis media associated with eosinophilic chronic rhinosinusitis

Allergology International, 2023
Background: Eosinophilic otitis media (EOM) is a refractory condition associated with eosinophilic chronic rhinosinusitis and bronchial asthma. EOM is characterized by type-2 inflammation and is refractory to various treatments.
Daiki Nakashima, Tsuguhisa Nakayama, Syunsuke Minagawa, Tetsuya Adachi, Chieko Mitsuyama, Yoko Shida, Tsuneya Nakajima, Shin-ichi Haruna, Yoshinori Matsuwaki   +8 more
doaj  

Dupilumab in children with eosinophilic esophagitis: a retrospective multicenter study

BMC Pediatrics
Background Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder characterized by symptoms of esophageal dysfunction and eosinophil-predominant inflammation. Dupilumab is a human monoclonal antibody that targets both IL-4 and IL-13 signaling.
Mohammed Hasosah, Ghassan Sukkar, Asharf AlSahafi, Ali Zaidan, Nouf Ghous, Abdulmajed Alshahrani, Ziyad Al Zahrani, Naif Hasosah, Mansour Qurashi, Loie Goronfolah, Ali Alsharief, Nagla Kamal   +11 more
doaj   +1 more source

Eosinophilic esophagitis in the "atopic march": dupilumab as an "umbrella" strategy for multiple coexisting atopic diseases [PDF]

Dupilumab is a monoclonal antibody targeting interleukin-4 and interleukin-13, approved for the treatment of multiple T2 diseases and more recently for Eosinophilic Esophagitis (EoE).
Del Giacco, Stefano, Demurtas, Mauro, Fantini, Massimo Claudio, Favale, Agnese, Lutzu, Nicola, Onali, Sara   +5 more
core   +1 more source

Lymphomatoid Papulosis Following Spesolimab Treatment for Generalised Pustular Psoriasis

Australasian Journal of Dermatology, EarlyView.
Mizuho Namba, Mika Matsumoto, Naoya Saito, Atsuko Kimura, Chihiro Sagara, Daiki Rokunohe, Eijiro Akasaka   +6 more
wiley   +1 more source

Dupilumab Reduces Urticaria Activity, Itch, and Hives in Patients with Chronic Spontaneous Urticaria Regardless of Baseline Serum Immunoglobulin E Levels

Dermatology and Therapy
Introduction In chronic spontaneous urticaria (CSU), interleukin (IL)-4 and IL-13 may promote mast cell activation directly via IL-4 receptor expression, or indirectly via upregulated immunoglobulin E (IgE) production.
Marcus Maurer, Thomas B. Casale, Sarbjit S. Saini, Moshe Ben-Shoshan, Elizabeth Laws, Jennifer Maloney, Deborah Bauer, Allen Radin, Melanie Makhija   +8 more
doaj   +1 more source

Alopecia areata after dupilumab for atopic dermatitis [PDF]

, 2018
Krystal Mitchell, J. Levitt
openalex   +1 more source

Omalizumab en práctica clínica dermatológica. Indicaciones, mecanismo de acción y factores predictivos de respuesta [PDF]

, 2019
El Omalizumab es un anticuerpo monoclonal anti-IgE aprobado para el tratamiento del asma y de la urticaria crónica idiopática refractaria al tratamiento con antihistamínicos H1.
Fernández Gutiérrez, Eva, García-Peñuela Arrechea, Íñigo   +1 more
core  

489 Dupilumab efficacy in atopic dermatitis in four randomized phase 3 trials (liberty ad solo 1&2, chromos, cafe) [PDF]

, 2018
Eric L. Simpson, Thomas Bieber, Marjolein de Bruin‐Weller, Andrew Blauvelt, Z. Chen, Marius Ardeleanu, Brad Shumel, B. Akinlade, Thomas Hultsch   +8 more
openalex   +1 more source